Grail is a startup with the goal of building a blood test screen for cancer in a bid to detect Cancer early has also just come together with Cirina a Hong Kong based company that is also in search of early cancer detection. The ambition is to possibly relate that work and knowledge into other diseases areas inclusive of course of early cancer detection.
Professor of Chemical Pathology who also is renowned for his work in noninvasive prenatal testing and Co-founder of Cirina; Dennis Lo partnered with Grail’s scientific advisory board as part of the merging and this move also turned to help Grail’s one day commercialize in Asia.
Since the commencement of Grail in 2016, it has generated over one billion dollars from sponsors in the likes of Jeff Bezos and Bill Gates together with top notch names in the pharmaceutical, health and technology industries also added to the list are Johnson and Johnson Innovation, ARCH Venture Partners, Amazon, Bristol-Myers Squibb, Celene and Merck.
Only a few months after Grail generated a Nine hundred ($900) million dollar Series B round, the startup target to detect cancer early on is looking for additional funding, CNBC reports. Before the Nine hundred million dollars round, grail had also generated a hundred million dollars to improve in prior studies of the blood test technology.
Referring to other sources, CNBC stated that Grail is particularly focused on sovereign funds. Grail has been said to contact with Mubadala, Abu Dhabi’s $125 billion sovereign fund and private equity firm SoftBank. The plan is to use the additional funding for its breast cancer clinical trial,which it announced in April.
The additional funding may also go toward buying back some of its shares from Illumina, its parent company. Meanwhile, Grail’s merger with Chinese company Cirina supposedly cost more than $100 million.
The ide a cancer-screening test is to identify the tiny bits of cancer DNA that are hanging out in our blood but are now undetectable. If companies like Grail are successful, they would be the first to pull off a cancer-detecting blood test that works proactively. The concept is similar to liquid biopsy tests, which use blood samples to sequence genetic information in that blood to figure out how tumors are responding to a certain cancer therapy.
With one sample of blood (the same you might have drawn at the doctor’s to check your cholesterol or blood-sugar levels), Grail’s plan is to sequence and screen for those bits with the hope that it will help catch cancer before it starts to be a full-blown problem.
Getting to that point won’t be easy, and Grail has started recruiting for large clincal trials, including one that plans to enroll 120,000 women.